About VolitionRX Ltd
- Industry: Health Care
- Exchange: NYSE MKT LLC
- Country: US
- Website: https://volition.com/
Frequently Asked Questions
What is the 52-week range for VNRX?
The 52-week high is $13.58 and the 52-week low is $0.2306.
What is the P/E ratio for VNRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for VNRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -376.59%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1043.10%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 9.37.
Analyst Recommendation Trends
Wall Street analyst consensus for VNRX over the last few months:
Latest VNRX News
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.
VolitionRx Participates in Launch of DETECSEPS Program in France
VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates, "Volition"), a multi-national epigenetics company, today announces, as part of the DETECSEPS Consortium, the official launch of the DETECSEPS project on the early detection of sepsis. The Consortium is funded with €6.3 million (~$7.3 million) from the French government.
VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of SepsisHENDERSON, Nev., Sept. 17,
These stocks are moving in today's after hours session
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.
By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment, all obligations under the Note have been satisfied. The senior secured convertible promissory note, dated January 7, 20
VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-03-17 | Plummer Nicholas | -7,003 | $0.19 | $1,331 |
| 2026-03-17 | Forterre Gael | -5,251 | $0.19 | $998 |
| 2026-03-17 | Micallef Jacob Vincent | -5,310 | $0.19 | $1,009 |
| 2026-03-17 | Rootsaert Rodney Gerard | -3,948 | $0.19 | $750 |
| 2026-03-01 | Plummer Nicholas | -5,867 | $0.213 | $1,250 |
| 2026-03-01 | Forterre Gael | -2,283 | $0.213 | $486 |
| 2026-03-01 | Rootsaert Rodney Gerard | -3,321 | $0.213 | $707 |
| 2026-02-26 | Batchelor Ann-Louise | +142,000 | - | - |
| 2026-02-26 | Plummer Nicholas | +187,000 | - | - |
| 2026-02-26 | Nguyen Kim | +178,000 | - | - |
| 2026-02-26 | Hughes Terig | +202,000 | - | - |
| 2026-02-26 | Kway Jasmine | +173,000 | - | - |
| 2026-02-26 | Micallef Jacob Vincent | +149,000 | - | - |
| 2026-02-26 | Innes Guy Archibald | +178,000 | - | - |
| 2026-02-26 | Rootsaert Rodney Gerard | +119,000 | - | - |
| 2026-02-26 | Rubin Ethel | +178,000 | - | - |
| 2026-02-26 | Forterre Gael | +149,000 | - | - |
| 2026-02-26 | Reynolds Cameron John | +486,000 | - | - |
| 2026-02-01 | Plummer Nicholas | -5,647 | $0.285 | $1,609 |
| 2026-02-01 | Forterre Gael | -2,010 | $0.285 | $573 |
| 2026-02-01 | Rootsaert Rodney Gerard | -3,196 | $0.285 | $911 |
| 2026-01-22 | Rubin Ethel | +12,000 | - | - |
| 2026-01-22 | Batchelor Ann-Louise | +33,900 | - | - |
| 2026-01-22 | Henshall Mickie | +12,000 | - | - |
| 2026-01-22 | Plummer Nicholas | +44,700 | - | - |
| 2026-01-22 | Nguyen Kim | +12,000 | - | - |
| 2026-01-22 | Forterre Gael | +38,100 | - | - |
| 2026-01-22 | Hughes Terig | +49,200 | - | - |
| 2026-01-22 | Butera Salvatore Thomas | +53,400 | - | - |
| 2026-01-22 | Kway Jasmine | +42,000 | - | - |
| 2026-01-22 | Barnes Phillip | +12,000 | - | - |
| 2026-01-22 | Micallef Jacob Vincent | +35,400 | - | - |
| 2026-01-22 | Innes Guy Archibald | +12,000 | - | - |
| 2026-01-22 | Rootsaert Rodney Gerard | +28,200 | - | - |
| 2026-01-22 | Colman Alan | +12,000 | - | - |
| 2026-01-22 | Reynolds Cameron John | +74,700 | - | - |
| 2026-01-22 | STILL TIMOTHY I | +90,000 | - | - |
| 2025-11-17 | Reynolds Cameron John | +20,000 | $0.35 | $7,000 |
| 2025-11-01 | Retter Andrew | -4,588 | $0.434 | $1,991 |
| 2025-11-01 | Plummer Nicholas | -5,647 | $0.434 | $2,451 |
| 2025-11-01 | Forterre Gael | -1,753 | $0.434 | $761 |
| 2025-11-01 | Butera Salvatore Thomas | -4,648 | $0.434 | $2,017 |
| 2025-11-01 | Rootsaert Rodney Gerard | -3,197 | $0.434 | $1,387 |
| 2025-10-14 | Innes Guy Archibald | +96,153 | $0.01 | $962 |
| 2025-10-14 | Innes Guy Archibald | +96,153 | $0.51 | $49,038 |
| 2025-10-14 | Reynolds Cameron John | +110,000 | $0.01 | $1,100 |
| 2025-10-14 | Reynolds Cameron John | +110,000 | $0.51 | $56,100 |
| 2025-10-14 | STILL TIMOTHY I | +48,076 | $0.01 | $481 |
| 2025-10-14 | STILL TIMOTHY I | +48,076 | $0.51 | $24,519 |
| 2025-10-04 | Batchelor Ann-Louise | -6,110 | $0.648 | $3,959 |
| 2025-10-04 | Plummer Nicholas | -8,146 | $0.648 | $5,279 |
| 2025-10-04 | Forterre Gael | -5,389 | $0.648 | $3,492 |
| 2025-10-04 | Butera Salvatore Thomas | -5,834 | $0.648 | $3,780 |
| 2025-10-04 | Michel Gaetan | -12,333 | $0.648 | $7,992 |
| 2025-10-04 | Micallef Jacob Vincent | -5,850 | $0.648 | $3,791 |
| 2025-10-04 | Rootsaert Rodney Gerard | -4,620 | $0.648 | $2,994 |